Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
1. A monoclonal antibody which binds EGFR extracellular domain and comprises heavy chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 7, 8, and 9, respectively, and light chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 10, 11 and 12, respectively.
2. A monoclonal antibody which binds EGFR extracellular domain and comprises a heavy chain variable region as set forth in SEQ ID NO: 21 and a light chain variable region as set forth in SEQ ID NO: 22.
3. The monoclonal antibody of claim 1 , wherein the antibody binds EGFR extracellular domain with a K D of better than 1 nM.
4. The monoclonal antibody of claim 1 , wherein the antibody is a human or humanized antibody.
5. The monoclonal antibody of claim 1 , wherein 1 the antibody is an IgG1.
6. The monoclonal antibody of claim 2 , wherein the antibody is a human or humanized antibody.
7. The monoclonal antibody of claim 2 , wherein the antibody is an IgG1.
8. The monoclonal antibody of claim 3 , wherein the antibody is a human or humanized antibody.
9. The monoclonal antibody of claim 3 , wherein the antibody is an IgG1.
10. A composition comprising the monoclonal antibody of claim 1 and a pharmaceutically acceptable carrier.
11. The composition according to claim 10 , which is a sterile composition.
12. The composition according to claim 11 , which is formulated for intravenous injection.
13. A composition comprising the monoclonal antibody of claim 2 and a pharmaceutically acceptable carrier.
14. The composition according to claim 13 , which is a sterile composition.
15. The composition according to claim 14 , which is formulated for intravenous injection.
16. A composition comprising the monoclonal antibody of claim 3 and a pharmaceutically acceptable carrier.
17. The composition according to claim 16 , which is a sterile composition.
18. The composition according to claim 17 , which is formulated for intravenous injection.
19. A composition comprising the monoclonal antibody of claim 5 and a pharmaceutically acceptable carrier.
20. A composition comprising the monoclonal antibody of claim 7 and a pharmaceutically acceptable carrier.
21. A composition comprising the monoclonal antibody of claim 9 and a pharmaceutically acceptable carrier.